Galmed Pharmaceuticals (GLMD) Projected to Post Earnings on Thursday

Galmed Pharmaceuticals (NASDAQ:GLMD) is expected to post its results before the market opens on Thursday, July 30th. Analysts expect Galmed Pharmaceuticals to post earnings of ($0.39) per share for the quarter.

Galmed Pharmaceuticals Price Performance

GLMD stock opened at $0.53 on Wednesday. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.59 and a beta of 0.75. The company has a fifty day moving average price of $0.58 and a 200 day moving average price of $0.63. Galmed Pharmaceuticals has a 12 month low of $0.41 and a 12 month high of $1.93.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.14% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.